Iopidine (Apraclonidine Hydrochloride)

Apraclonidine acts as a selective alpha‑2 adrenergic receptor agonist in the eye. Activation reduces aqueous humor production and modestly increases uveoscleral outflow, leading to lower intra‑ocular pressure.

The prescribed dose is determined by the treating eye‑care professional. Typically, one drop is instilled into the affected eye(s) once or twice daily, but exact frequency and duration are individualized.

Iopidine is classified as Pregnancy Category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy or lactation only if the potential benefit justifies the potential risk; consultation with a physician is essential.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iopidine belongs to the alpha‑2 adrenergic agonist class, offering a different mechanism than beta‑blockers like timolol. It can be used alone or in combination with other agents, and may be preferred when patients cannot tolerate beta‑blockers or need an additional pressure‑lowering effect.

Store Iopidine at room temperature, preferably below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing.

Iopidine is applied topically. After washing hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac. Close the eye gently for a few seconds and avoid touching the dropper tip to any surface.

Serious risks include allergic reactions such as eyelid swelling or rash, severe ocular inflammation (uveitis), systemic hypotension leading to dizziness or fainting, and rare cardiac arrhythmias. Patients should seek immediate medical attention if any of these occur.

Iopidine should be avoided in individuals with known hypersensitivity to apraclonidine or any component of the formulation, in patients with severe cardiovascular disease where systemic hypotension could be hazardous, and in pregnant women unless clearly indicated by a physician.